Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pert ...
Everyday Health on MSN
Diagnosed With ATTR-CM: What Should I Do Now?
After a diagnosis of the heart disease transthyretin cardiac amyloidosis (ATTR-CM), starting treatment and talking to your ...
Pertuzumab-dpzb is the first interchangeable biosimilar to pertuzumab, enhancing treatment accessibility for HER2-positive ...
US FDA approves Henlius and Organon’s Poherdy, the first Perjeta biosimilar: Shanghai Tuesday, November 18, 2025, 16:00 Hrs [IST] Shanghai Henlius Biotech, Inc., a global health ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative medicine, will attend the Innovations in Wound Care ...
TONMYA is now available by prescription and available for pharmacy ordering nationwideTONMYA is the first FDA-approved treatment for fibromyalgia ...
NPM1 mutations, one of the most common genetic drivers of AML, are now actionable for patients –– Acute unmet need in R/R ...
TONMYA was approved by the FDA on August 15, 2025.
Several observations from preclinical and short-term clinical studies support a role for sildenafil in the treatment of heart failure patients. The following discussion briefly considers each of these ...
The Cardiac Biomarkers Market offers opportunities in developing high-sensitivity assays, point-of-care solutions for decentralized care, and AI-supported diagnostics. Growth is driven by rising ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial ...
The study highlights alarmingly high levels of antibiotic-resistant bacteria in participants from India, underscoring the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback